Martin Low has founded or co-founded eight companies including Eradivir, Inc., where he has been CEO since inception in March of 2020.  Prior to Eradivir, Inc., he served as CEO for 9 years at On Target Labs, another biotech he co-founded.  Under his leadership two drugs were brought into the clinic with the lead drug successfully filed with the FDA for approval in ovarian cancer. Throughout his career he has been successful in raising funds and securing partnerships.  For On Target, he raised $90M and secured partnerships with several key Medtech companies.  Martin has introduced several products that have won awards from Business Week, The Thomas Edison Foundation and the Smithsonian Institute. Martin has degrees from Purdue University and Northwestern’s Kellogg Graduate School of Management.